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Abstract 
Background 
Depression is a serious disorder which significantly impacts wellbeing and quality of 
life. Studies exploring mental wellbeing in the transgender population are mostly 
limited by small, non-homogenous samples and lack of matched controls. This study 
aimed to address these limitations and explore depression rates in a large sample of 
transgender people, compared with matched controls from the general population, as 
well as factors predicting depression in those taking cross-sex hormone treatment 
(CHT) compared to those not. 
Methods 
Transgender individuals (n=913) completed a measure of depression, measures 
which predict psychopathology (self-esteem, victimization, social support, 
interpersonal problems), and information regarding CHT use. Participants were 
matched by age and experienced gender with adults from the general population who 
had completed the measure of depression. 
Results 
Individuals were categorized as having no, possible or probable depressive disorder. 
Transgender individuals not on CHT had a nearly four-fold increased risk of probable 
depressive disorder, compared to controls. Older age, lower self-esteem, poorer 
interpersonal function and less social support predicted depressive disorder. Use of 
CHT was associated with less depression.  
Limitations  
Participants were attending a national gender identity service and therefore represent 
only a sub-group of transgender people. Due to the cross-sectional design, 
longitudinal research is required to fully confirm the finding that CHT use reduces 
depression. 
Conclusion  
This study confirms that non-treated transgender individuals have an increased risk of 
a depressive disorder. Interventions offered alongside gender affirming treatment to 
develop interpersonal skills, increase self-esteem and improve social support may 
reduce depression and prepare individuals for a more successful transition. 
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1. Introduction 
Depression is one of the most commonly diagnosed mental disorders (Kessler et al., 
2012) and one of the most intensely researched. Recent estimates suggest that 
depression affects around 350 million people globally and is one of the leading 
cause of disability worldwide (WHO, 2016). Efficaciousness of treatments (NICE, 
2009) as well as identification of co-morbid disorders (such as anxiety, obsessive-
compulsive disorder, and substance abuse), has led to a better understanding of this 
mental disorder. Depression has been found to be associated with a number of co-
occurring factors, such as age (Stordal et al., 2003), being female (Girgus et al., 
2017; Kessler, 2003), experiencing victimization (Collier, 2013), having less social 
support (Paykel, 1994), lower self-esteem (Sowislo & Orth, 2013) and poorer 
interpersonal functioning (Barrett & Barber, 2007; McFarquhar et al., 2018). As a 
result, some populations may be more at risk than others. 
 
Indeed, depression has been found to be more prevalent in the LGBTQ (Lesbian, 
Gay, Bisexual, Transgender and Questioning) population compared to the general 
population (Marshal et al., 2011). It has been hypothesized that vulnerability to 
develop depression in the LGBTQ population relates to the stress experienced by 
this group. The Minority Stress model (Meyer, 1995) suggests that this can largely 
be explained by stressors induced by a hostile, homophobic, trans phobic culture, 
which often results in a lifetime of harassment, abuse, victimization, and 
discrimination (Meyer et al., 2008). However, in many studies that have explored the 
mental health of LGBT individuals, the samples have predominately consisted of 
LGB individuals, and have included very small numbers of transgender people (Haas 
et al., 2010; Walls et al., 2010). Thus, the prevalence, seriousness, and comorbidity 
of depression in the transgender population is still poorly researched and 
understood.   
 
Transgender individuals are those whose gender identity does not match the sex 
assigned at birth (Bouman & Arcelus, 2017). Some may present themselves in a way 
that is not within the traditional binary dichotomy of man/woman (Warren et al., 2016; 
Richards et al., 2016). A number of transgender people will choose to use cross-sex 
hormone treatment (CHT) and/or gender affirming surgery to feminize or masculinize 
their bodies (Richards et al., 2016). Although recent systematic reviews have found 
that prevalence rates of transgender people is not high (Arcelus et al., 2015), most 
studies are limited by focusing on those attending services. Recent population studies 
indicate a clear increase in the number of transgender people in society (Arcelus et 
al., 2015; Flores et al., 2016; Kuyper & Wijsen, 2014) and evidence of this is the 
increase in prevalence rates of transgender individuals presenting to specialist 
transgender health services in western countries (Arcelus et al., 2015; Collin et al., 
2016). Recent studies have found that 0.6% of the American population is described 
as transgender (Flores et al., 2016). Population studies in the Netherlands and 
Belgium show similar results (Kuyper & Wijsen, 2014; Van Caenegem, 2015). 
Transgender people describe personal struggles with coming out and disclosing their 
gender identity (Bockting & Coleman, 2016), with many experiencing discrimination 
and victimization (Adams et al., 2016; Bockting et al., 2014; Claes et al., 2015), 
including rejection from family and others (Koken et al., 2009).  
 
It is, therefore, not surprising that transgender people are reported to suffer from a 
high prevalence of mental health problems, most notably anxiety and depression 
(Bockting et al., 2013; Bouman et al., 2016; Davey et al., 2014; Dhejne et al., 2016; 
Heylens et al., 2014; Hoffman, 2014; Millet et al., 2016), low self-esteem (Erich et al., 
2010), self-harm (Davey et al., 2016; Marshall et al., 2016) and disordered eating and 
poor body image (van de Grift, 2016a, 2016b; Witcomb et al., 2015). Previous 
research with cross-sectional data has found that transgender individuals have high 
levels of anxiety; higher than found in other groups or normative data (Bouman et al., 
2016a). 
 
In relation to depression, while the number of studies are limited, those that have been 
carried out report associations between depression and frequent experiences of 
discrimination in employment and housing, sexual violence, physical and verbal 
abuse, societal harassment related to gender presentation, a perceived need to keep 
one’s transgender identity a secret, higher levels of minority stress and lower levels of 
social support [e.g., Bazargan & Galvin, 2012; Bockting et al., 2014; Bouman et al., 
2016b; Clements-Nolle et al., 2006; Huffaker & Kwon, 2016; Leppel, 2016; McNeil et 
al., 2012; Nemoto et al., 2011). Hoffman (2014) recently reviewed the literature on 
depression in transgender women and reported that interactions with other people – 
both positive via social support and negative via discrimination and abuse – are 
important predictors of depression.  
 
Given that depression may be related to pre-transition problems or the transition itself, 
many studies have compared prevalence of depression between individuals who have 
and have not received gender affirming medical treatment (i.e., either cross-sex 
hormone treatment (CHT) or CHT and gender affirming surgery (GAS) (Bouman et al., 
2016b; Colizzi et al., 2014; Davis & Colton Meier, 2014; De Vries et al., 2014; Gómez-
Gil et al., 2012; Heylens et al., 2014; Colton Meier et al., 2011) in order to try to 
ascertain whether depressive symptomology is alleviated by such interventions. 
Although the majority of these studies show that transgender people not on CHT 
experience higher levels of depressive symptomatology than those on treatment 
(Colizzi et al., 2014; Davis & Colton Meier, 2014; De Vries et al., 2014; Gómez-Gil et 
al., 2012;  Heylens et al., 2014; Colton Meier et al., 2011), the results are not consistent 
[e.g., Reisner et al., 2015). Indeed, the association between CHT and depression is 
likely to be influenced by stigma (felt and enacted) (Bockting et al., 2013) which may 
not always be lessened by receiving cross-sex hormone treatment or gender affirming 
surgery, nor may be wanted by all transgender people (Beek et al., 2015). 
 
While these studies begin to paint a picture of the prevalence of depressive 
symptomology in the transgender population, there are a number of methodological 
limitations in the findings of the aforementioned studies. Firstly, the studies often 
include a non-heterogeneous group of transgender people, for example, those at 
different stages of transition (e.g., Bockting et al., 2014). This is the case for the studies 
exploring the use of the CHT and may go some way to explain the inconsistencies 
found. Transition stage is a crucial variable as those people further through their 
journey may have developed increased resilience over time and increased social 
support and affirmation of their gender identity (Bockting & Coleman, 2016). This is 
therefore likely to be an important variable that needs to be considered and controlled 
for when exploring aspects of mental health and wellbeing in the transgender 
population. Secondly, while some have used comparison groups, which provide a 
degree of control, none of these studies have used matched control data to control for 
known factors that affect depression symptoms, such as age and gender (Arbus et al., 
2014; Baxter et al., 2013). Finally, studies most often tend to involve small samples 
sizes which may undermine reliability (Button et al., 2013). 
 
To address the aforementioned limitations of small sample size, lack of matched 
control groups and non-homogeneity, the current study aimed to recruit a large cohort 
of adult transgender individuals, all at the same stage of accessing clinical services, 
and to compare them to a large cohort of adults recruited from the general population, 
matched by age and (experienced) gender. The study had three aims. Firstly, to 
determine the levels of depressive symptomatology suggesting no, possible and 
probable depressive disorder in non-treated transgender people accessing treatment 
(thereby excluding any transgender person who may already be on cross-sex 
hormones) and to compare them with a cisgender (person whose gender identity 
corresponds with their birth sex) matched sample from the general population. 
Secondly, to investigate the predictive role of variables known to be associated with 
depressive symptoms (age, assigned gender, self-esteem, social support, 
interpersonal function, and victimisation, and the use of CHT). Finally, to investigate 
differences in depressive scores between transgender people on cross-sex hormone 
treatment (CHT) with those not on cross-sex hormone treatment (non-CHT).  
 
Based on the literature on depression in the transgender population it was 
hypothesized that levels of depression will be higher in the transgender population 
compared to the general population, and will be associated with older age, decreased 
self-esteem and social support, discrimination, lower levels of interpersonal function 
and lack of CHT treatment.  No prediction was made regarding potential differences 
between transgender males and females. Physiological evidence points towards a 
possible genetic aetiology for depression which might manifest in differences based 
on birth assigned gender (e.g., Bangasser et al., 2016), while more social explanations 
may predict differences based on levels of hardship and discrimination experienced 
(expected to be higher for both cis and transgender women). 
 
2. Methods 
2.1 Participants and Procedures 
2.1.1. Transgender participants 
The sample consisted of all individuals (n=1069) invited for assessment at a national 
transgender health service in the United Kingdom (UK) during a 3-year period from 
November 2012 to October 2015, who self-identified as transgender. Prior to the 
clinical assessment every patient was sent a questionnaire pack, consisting of the 
standard demographic and history questionnaires required as part of routine care, as 
well as the study questionnaires, an information sheet and consent form. If consent 
was given, participants returned all of the questionnaires by mail, in the envelope 
provided. If consent was not given, participants returned only the standard 
questionnaire. The refusal/non-response rate was 2.3%. The study received ethical 
approval from the NHS Ethics committee and from the Research and Development 
Department from the Nottinghamshire Healthcare NHS Foundation Trust in line with 
Health Research Authority guidance (Health Research Authority, 2013). For the first 
aim of the study, in order to have a homogenous group, only those individuals who 
were not on any cross-sex hormones (non-CHT) before assessment were eligible to 
be included in this analysis. For the second and third aims, the full sample was 
included. 
 
2.1.2. Control group 
A sample of 3816 male and female adults from the general UK population who were 
recruited between 2006 and 2009 for a different study (Crawford, 2009) were used as 
controls and matched by age and gender to the transgender sample. The normative 
data of the control sample was purposefully broad, having selected a wide 
representation of the general adult UK population, in terms of age, education, and 
gender (although, in most cases, females were over sampled). Participants were 
recruited from a variety of sources, including both large and small businesses, public 
service organizations, community centres, and recreational groups. Both urban/ 
suburban and rural-semi-rural locations were represented in the sample, although 
recruitment was greater in the former locations. Participants were invited to complete 
the Hospital Anxiety and Depression Scale (Zigmond & Snaith, 1983) and, if they 
consented, to return completed questionnaires in a sealed envelope. The 
questionnaires were filled out anonymously. The combined refusal/non-return rates 
ranged from approximately 17% to 21%. Ethical approval for this study and the 
previous studies had been obtained from the Psychology Ethics Committee of the 
University of Aberdeen, Aberdeen, United Kingdom. 
 
2.2. Main Outcome Measures 
 
2.2.1. The Hospital Anxiety and Depression Scale (HADS) (Zigmond  & Snaith, 1983) is 
a 14-item self-report screening scale that was originally developed to indicate the 
possible presence of anxiety and depression states in the setting of a medical non-
psychiatric outpatient clinic.  The HADS consists of two subscales, HADS-Anxiety 
(HADS-A) and HADS-Depression (HADS-D). For this study only the subscale of 
depression will be used. This subscale has seven items, rated on a 4-point Likert scale 
(ranging from, as much as I always do (0); not quite so much (1); definitely not so 
much (2); to not at all (3)), indicating symptoms of depression during the preceding 
week.  A score of 0-7 on either scale is regarding as being in the non-clinical range 
(no symptoms), a score of 8-10 is suggestive of the presence of a depressive disorder 
(possible symptoms), and a score of 11 or higher indicates the probable presence of 
a depressive disorder (symptoms).  Maximum subscales scores are 21. The HADS 
was found to perform well in assessing the symptom severity and caseness of 
depressive disorders in both somatic, psychiatric and primary care patients and in the 
general population (Bjelland et al., 2002) and it has been previously used with 
transgender individuals (Colizzi et al., 2014; Gómez-Gil et al., 2012). A number of 
researchers have explored HADS data to establish the cut-off points for caseness of 
depression and a systematic review of a large number of studies identified a cut-off 
point of 8/21 for depression (Bjelland et al., 2002). For depression (HADS-D) this gave 
a specificity of 0.7 and a sensitivity of 0.9. In this study, the Cronbach’s alpha was 
0.76. 
 
2.2.2. The Rosenberg Self-Esteem Scale (RSE) (Rosenberg, 1965) is a self-report 
measure of global self-esteem. Items are rated on a 4-point rating scale ranging from 
0 (‘Strongly disagree’) to 3 (‘Strongly agree’). Its total score is calculated by summing 
the item scores with higher scores indicating higher self-esteem.  The RSE has been 
empirically validated and administered previously to transgender individuals (Arcelus 
et al., 2016; Vocks et al., 2009). In this study, the Cronbach’s alpha was 0.91. 
 
2.2.3. The Experiences of Transgender Phobia Scale (Lombardi et al., 2001) 
assesses experiences of discrimination or victimization on the basis of gender identity 
or gender presentation. The questionnaire was based on the Transgender Violence 
Study and measured people’s lifetime experiences of violence and harassment and 
experiences of any form of economic discrimination as a result of being transgender 
(e.g., verbal abuse, physical abuse, fired from a job, problems getting a job, and 
problems getting health or medical services due to gender identity or presentation). 
All five items are to be rated on a four-point Likert scale ranging from 0 (‘never‘) to 3 
(‘several times’). This scale has been previously used with transgender individuals 
(Arcelus et al., 2016; Bouman et al., 2016c; Claes et al., 2015; Colizzi et al., 2014). In 
this study, the Cronbach’s alpha was 0.59. 
 
2.2.4. The Multidimensional Scale of Perceived Social Support (MSPSS) (Zimet et al., 
1990) is a 12-item, self-report scale designed to tap social support from family, friends, 
and significant others. Items are rated on a 7-point Likert scale ranging from 1 (‘very 
strongly agree’) to 7 (‘very strongly disagree’). The instrument includes three 
subscales to address these three types of support (family, friends, significant others). 
The mean total and subscale scores range from 1 to 7, and a higher score indicates 
greater perceived social support. This scale has recently been used in transgender 
populations (Boza & Perry, 2014; Davey et al., 2014). In this study, the Cronbach’s 
alpha was 0.89. 
 
2.2.5. The Inventory of Interpersonal Problems (IIP-32) (Barkham, Hardy & Startup, 
1996) measures interpersonal difficulties. It consists of 32 items to be rated on a 5-
point Likert scale ranging from 0 (‘Not at all’) to 4 (‘Extremely’). There are eight 
subscales of interpersonal problems: Hard to be Assertive, Hard to be Sociable, Hard 
to be Supportive, Hard to be Involved, Too Dependent, Too Caring, Too Aggressive, 
and Too Open. A total mean score provides a global measure of interpersonal distress. 
Higher subscale scores indicate greater interpersonal difficulties. The IIP-32 is a 
shortened version of the original IIP, yet the psychometric properties are retained; a 
confirmatory factor analysis demonstrated high reliability with alpha coefficients of 
0.70 to 0.88 (Barkham et al., 1996). The IIP-32 has been successfully used in both 
non-clinical (Berry et al., 2006) and clinical samples (Bouman et al., 2016c, Davey et 
al., 2015]. In this study, the Cronbach’s alpha was 0.87. 
  
2.3. Data Analysis 
All quantitative data analyses were performed by means of SPSS 22 (IBM, 2013). 
Based on HADS-D scores, individuals were grouped into one of three categories: 1) 
people with no depressive disorder, 2) people with symptoms suggesting of a possible 
depressive disorder and, 3) people with symptoms suggesting a probable depressive 
disorder. For Aim 1, only transgender people not on cross-sex hormones were 
included in order to have a homogenous group. Both groups will be matched according 
to age and experienced gender. As the control group identified themselves based on 
the binary notion of gender (male and female), in order for the matching to be possible 
only transgender people who identified as male or female will be selected. 
Transgender non-binary people will not be included.  The chi-square test statistic was 
used to compare the frequency with which transgender and general population adults 
fell into each of the three depressive symptomology categories (no, possible, or 
probable depressive disorder). For the remaining aims, all transgender individuals 
were included. For Aim 2, a binary logistic regression analysis was performed to 
explore the predictive value of the other measures of psychopathology, wellbeing, and 
hormone use on the presence/absence of depressive symptomology. For Aim 3, 
frequency of inclusion in each depressive symptomology category was compared 
between transgender people on cross-sex hormones and those not on cross-sex 
hormones using the chi-square test statistic. The level of significance for all analyses 
was set at p < 0.05. See Figure 1 for an illustration of the cohorts for each aim and the 
exclusions. 
 
(Insert Figure 1. about here) 
 
 
3. Results 
3.1. Socio-demographic characteristics of the transgender sample 
The age range of the 1069 transgender individuals invited to participate was 15-79 
years with a mean age of 30.4 years (SD = 13.9). Of these, 25 (2.3%) did not consent 
and a further 131 participants (12%) identified themselves as non-binary (i.e., not 
identifying with either an exclusive male or female identity) and so were excluded from 
the analysis. Of the remaining 913 participants, 582 (63.7%) participants identified 
themselves as transgender females (assigned male at birth) and 331 (36.3%) as 
transgender males (assigned female at birth). Of the total sample of 913 transgender 
people, 638 (69.9%) were not on cross-sex hormone treatment and 261 (28.9%) were 
on cross-sex hormone treatment. Fourteen patients had missing data, relating to either 
their use or not of cross-sex hormones (14; 1.5%) leaving a final sample size of 
(n=899). 
 
3.2. Aim 1: Comparative analyses between transgender people not on CHT and 
controls.  
For the first aim of the study only people not on CHT were selected (n=638). The age 
range of this group was 16-79 years with a mean age of 28.6 years (SD =12.8). This 
group was matched by age and experienced gender with the control group. However, 
46 (7.2%; 18 transgender females and 28 transgender males aged 17 and 18 with an 
average age of 17.3 years [SD = 0.48]) could not be matched due to insufficient 
numbers for that age in the control data.  Therefore, this gave a final sample of 1184 
participants; 592 non-CHT patients who were matched with 592 participants in the 
control population database. Taking these together, 436 (36.8%) were transgender 
and cisgender females and 748 (63.2%) were transgender and cisgender males. 
 
In the category of ‘No Depressive Disorder’, the control group was significantly more 
prevalent than the transgender group. In contrast, the transgender group was 
significantly more prevalent in the categories ‘Possible Depressive Disorder’ and 
‘Probable Depressive Disorder’ compared to the control group. This difference was 
statistically significant [Χ2(2) = 223,388, p < .001]. Furthermore, when analysed 
separately by identified gender, the difference in prevalence remained statistically 
significant. That is, the control group was more prevalent in the ‘No Depressive 
Disorder’ category and the transgender group was more prevalent in the ‘Possible 
Depressive Disorder’ and ‘Probable Depressive Disorder’ categories in analyses that 
compared cisgender and transgender men [Χ2(2) = 149.163 p < .001] and cisgender 
and transgender women [Χ2(2) = 74.814, p < .001]). 
 
(Insert Table 1. about here) 
 3.3. Aim 2: Predictors of the presence/absence of depressive disorder (probable 
and possible) among the whole transgender population. 
 
In order to explore the predictors of depression in the transgender population, the data 
from all of the transgender people were analyzed (n=899). Those in the category of 
probable and possible depressive disorder were grouped together into one category 
(depressive disorder).  Linear regression analysis was performed with the presence 
or absence of depressive disorder as the dependent variable, and age, gender, self-
esteem, social support, interpersonal function and victimization and presence and 
absence of CHT as independent variables. The results showed that four of these 
variables were significant predictors for a transgender person attending a health 
service to suffer from a depressive disorder; higher age, lower social support, lower 
self-esteem, and greater interpersonal problems (See Table 2). 
 
 
(Insert Table 2. about here) 
 
 
3.4. Aim 3: Comparative analyses between transgender people on CHT and those 
not on CHT. 
 
Analyses comparing transgender people on CHT (n=261) with those not on CHT 
(n=638) found a statistically significant difference between the groups. There were 
more transgender people using CHT in the category of no depressive disorder 
compared to those not on CHT [Χ2(1) = 11,556, p < .001]. The latter group was more 
prevalent in the category depressive disorder (see Table 3.). A comparison of the 
pattern within each group found that for both transgender males and transgender 
females there were more transgender people in the depressive disorder category who 
were not on CHT compared to those who were (transgender females; [Χ2(1) = 6,709, p 
< 0.05]) and transgender males; [Χ2(1) =4,535, p < 0.05]). 
 
 (Insert Table 3. about here) 
 
 
4. Discussion 
 
Depression is a common mental disorder. Globally, rates of depression are high and 
depression is associated with great disease burden and for this reason it is one of the 
conditions that is targeted by the WHO’s Mental Health Gap Action Programme (WHO, 
2016). While the precipitating factors are many and varied, certain groups may be at 
an increased risk of developing depressive symptomology. In line with this, this study 
found high rates of possible (13%) and probable (11%) depression in untreated 
treatment seeking transgender people attending a transgender health service in the 
UK. Overall, there was a significantly higher prevalence of transgender people 
reporting depressive symptomology than controls – an almost 4-fold increased risk - 
and this pattern was evident when comparing both males (cis and trans) and females 
(cis and trans). Within the full transgender group (treated and untreated), older age, 
less social support, lower self-esteem, and greater interpersonal problems were 
significant predictors of depressive symptomology, and both transgender males and 
transgender females were more likely to be in the depressive disorder categories if 
they were not on cross-sex hormones. 
 
While some mental health disorders, such as anxiety (McLean et al., 2011), post-
traumatic stress disorder (Mendoza et al., 2016) and depression (Fellinger et al., 2018; 
Fisher et al., 2017) often present as more prevalent in females, with explanations 
linked to variations in the effects of sex hormones (e.g., estrogen and progesterone, 
corticotropin-releasing factor (CRF), and neurotransmitters such as serotonin) on the 
fight or flight response (Bangasser  et al., 2016), which may vary across the menstrual 
cycle (Rohleder et al., 2001), here gender did not appear to differentiate between risk 
for depression. This suggests that the increased risk that transgender individuals 
appear to face may be more related to their experiences of being transgender, rather 
than their birth assigned physiology. Indeed, for transgender people in particular, the 
experience of minority stress [Meyer, 1995; 2003) is significant and likely plays a 
greater role (Davey et al., 2014).  
 
Older age, less social support, lower self-esteem, and greater interpersonal problems 
were significant predictors of depressive symptomology in treated and untreated 
transgender people. These variables are often inextricably linked; those with little 
social support are likely to have reduced self-esteem and this may influence their 
interpersonal functioning. Or indeed poor interpersonal functioning may lead to 
difficulties in relationships which can lead to a limited social network on which one can 
rely on for support. Although in some circumstances individuals can develop coping 
mechanisms over time which can lead to reduction in depression (Nuttbrock et al., 
2010), here depression was predicted by older age which may reflect the cumulative 
effect over the years of the other variables (i.e., longer period of lack of social support) 
or greater difficulties in coming out when older and experiencing transphobia as a 
more recent occurrence (Singh & Bower, 2017). Identification of such predictor 
variables is important as it provides a richer insight into the experiences of transgender 
people. Rather than simply reporting that depression is higher, we seek to understand 
what factors might be associated with this, in order to develop ways to support 
transgender people. That is, to focus on the factors implicated in the development and 
maintenance of depression. In line with this, the finding that social support, self-
esteem, and interpersonal problems are significant suggests that these could be 
valuable areas for clinicians to work on with their clients, in addition to addressing the 
presenting symptoms in the usual ways (therapy and/or pharmacological 
interventions) (McFarquhar et al., 2018). Interventions in other areas, with other client 
groups, have found effective ways to increase self-esteem (Fennell, 2006; Morton et 
al., 2012; Rigby & Waite, 2007) and interpersonal psychotherapy (IPT) has been 
shown to improve interpersonal functioning (e.g., Arcelus et al., 2011; Hara et al., 
2000; Mufson et al., 2013) and these could be easily translated to the transgender 
population. Delivering such interventions alongside facilitating peer support, either 
face-to-face or online, may be one way in which clinicians can assist in developing 
social support for their clients. Indeed, peer support can offer avenues to greater social 
connectedness, increased confidence and ability to challenge stigma in a safe space, 
insight into health decisions from hearing shared experiences, and potentially 
increased awareness of mental health struggles which may lead to increases in help 
seeking behavior (Naslund et al., 2016). 
 
Satisfaction with support also appears to be key (McNeil et al., 2012); i.e., quality not 
quantity. Indeed, being able to effectively utilize social support has been implicated in 
lower levels of depression in transgender women (Clements-Nolle et al., 2011) in 
contrast to more avoidant coping strategies) (Mepham et al., 2014) and therefore 
working with families to ensure that the support that is being given is serving the need 
of the transgender person, for example in increasing self-efficacy (Bouman et al., 
2016b), may be valuable. Focusing on these factors may help to reduce transgender 
individuals’ likelihood of experiencing depression, and/or increases in depression, 
when going through their transitional process.  
 
The analysis comparing transgender individuals on cross-sex hormone treatment with 
those not on such treatment confirmed that there are apparent benefits to the use of 
hormones on depressive symptomology and reflects the benefits reported firsthand by 
clinicians and within the literature (Bouman et al., 2016b;  Davis et al., 2014; De Vries 
et al., 2014; Gómez-Gil et al., 2012; Heylens et al., 2014), although these findings 
need to be replicated in longitudinal studies. This can be taken as further evidence to 
support the argument that early initiation of gender confirming treatment for 
transgender people is beneficial to the long term mental wellbeing of transgender 
individuals and that access to cross–sex hormones should be made available at the 
earliest possible point. Currently, many people resort to purchasing hormones via the 
internet which carries inherent dangers (Mepham et al., 2014). This is because the 
pathways to care within the UK are extremely prescriptive which serves to draw out 
the time taken to time to access hormones (Coleman et al., 2010; Wylie et al., 2014). 
This is in addition to already long waiting times to be seen by a specialist clinical 
service due to the limited number that exist and increasing numbers of referrals. 
Changes to the infrastructure and processes available would serve to help 
transgender individuals access hormone treatment earlier, if desired. However, due to 
the cross-sectional nature of this study, the direction of effect in unknown. That is, 
whether the positive impact on psychological wellbeing associated with the use of CHT 
is a consequence of starting the process of gender role transition, or whether those 
who start CHT before a specialist assessment do so because they have greater self-
esteem, better interpersonal relationships and more social support - possibly from 
other trans friends who may guide them - and are therefore in a better position to 
embark on CHT without the assistance of a medical professional.  
 
The global generalizability of these findings needs to be borne in mind. Waiting times 
in the UK are long (currently between 12-14 months) and the UK legislation on access 
to free healthcare for transgender people, as well as legislation such as the Gender 
Recognition Act 2004 and the Sex Discrimination (Gender Reassignment) Regulations 
Act 1999 and 2008, mean that the experiences of transgender people in the UK may 
be very different from that of trans people in other countries (Davey et al., 2015). These 
differences are further emphasized when considering how changes to diagnosis might 
affect access to care differently in different countries (Beek et al., 2016). Within the 
UK trans population, these results may only be generalizable to transgender 
individuals who have chosen to access care via transgender health services, which 
therefore fails to capture those who have yet to seek treatment (Zucker & Lawrence, 
2009).  However, a major strength of this study and one which seeks to address 
methodological criticisms of past research (e.g., Dhejne et al., 2011) is the use of a 
matched control sample (transgender and controls matched on experienced gender; 
transgender on CHT and not on CHT); a method we have used previously (Witcomb 
et al., 2015). Regarding sample size, this study is, to our knowledge, one of the largest 
studies in the field. It is worth noting, however, that 12% of the participants invited to 
participate identified themselves as being non-binary; identifying neither with their birth 
assigned gender, nor the opposite gender. These participants were excluded, so as 
to maintain homogeneity, since recent studies suggest that non-binary people may 
have poorer health than binary transgender people (Orre et al., 2017; Rimes et al., 
2017; Warren et al., 2016; Zeluf et al., 2016). However, as the prevalence of people 
identifying as non-binary is increasing (Richards et al., 2016) it is possible that some 
of our transgender participants may ultimately endorse a non-binary gender as 
opposed to a binary transgender identity. Furthermore, our control population was not 
asked about their gender identity and so it is possible that this population may include 
some transgender and non-binary people. However, since the number of non-binary 
people seen within the service, as well as the prevalence of transgender individuals 
within the general population, is very low overall, this is unlikely to pose a major 
methodological concern. But, we do propose that in the future matching may be more 
accurate when done on the basis of birth assigned gender, and that binary and non-
binary transgender cohorts be included within studies together. Indeed, since our 
control group was taken from a general population sample, it may also be useful to 
compare depression rates in binary and non-binary trans people with control 
participants from both non-clinical and clinical populations to get a better picture of the 
rates of depression experienced.  
 
Overall, this study highlights the need for clinical services to properly assess 
depressive symptomology, and associated predictor variables, in treatment-seeking 
transgender individuals and to expedite the use of cross-sex hormones, where 
appropriate, in order to improve mental health. Here, untreated transgender people 
had higher prevalence rates of possible or probable depressive disorder than controls 
and trans people already on cross-sex hormones. Higher age, lower self-esteem, 
lower social support and poorer interpersonal functioning all predicted depressive 
disorders. Focused interventions that primarily aim to increase self-esteem, social 
support and interpersonal functioning may prove to be useful in increasing the quality 
of life of transgender people. 
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Figure 1: Diagram to show the cohorts for each aim of the study and the exclusions. 
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Table 1: Number of transgender (TG) people and controls with no depressive disorders, and depressive disorders (possible and probable) (n=1184)  
 
*p<.05 
 Both Genders 
(n=1184) 
Females 
(n=436) 
Males 
(n=748) 
TG 
(n=592) 
Controls 
(n=592) 
TG 
(n=218) 
Controls 
(n=218) 
TG 
(n=374) 
Controls 
(n=374) 
No depressive disorder n(%) 309 (26.1)* 539 (45.5)* 112 (25.7)* 194 (44.5)* 197 (26.3)* 345 (46.1)* 
 
 
Depressive 
disorders n(%) 
 
 
Possible  n(%) 154 (13.0) 39 (3.3) 59 (13.5) 17 (3.9) 95 (12.7) 22 (2.9) 
 
Probable n(%) 
 
129 (10.9) 
 
14 (1.2) 
 
47 (10.8) 
 
7 (1.6) 
 
82 (11.0) 
 
7 (0.9) 
Total possible + probable n(%) 283 (23.9)* 53 (4.5)* 106 (24.3)* 24 (5.5)* 178 (23.7)* 
 
29 (3.8)* 
 
  
 
Table 2. Predictive role of age, gender, self-esteem, social support, interpersonal function and victimization in transgender people with possible and probable 
depressive disorder (as one category) compared to transgender people with no depressive disorder. 
 
 
  
          Exp(B)              p B SE Wald 
 Age ,017 ,008 5,028 1,017 ,025 
Assigned Gender ,230 ,187 1,512 1,259 ,219 
CHT pre assessment ,009 ,196 ,002 1,009 ,963 
Global score MSPSS -,015 ,006 6,257 ,985 ,012 
Total RSE -,118 ,018 44,706 ,889 ,000 
Global IIP score ,911 ,163 31,149 2,488 ,000 
Total Transphobia ,012 ,035 ,112 1,012 ,737 
 Constant ,281 ,622 ,204 1,325 ,651 
a. Dependent Variable: presence/absence of depression (HADS) 
 
 
 
  
Table 3. Depressive disorders based on the HADS in transgender people on cross-sex hormone treatment (CHT) and those not on cross-sex hormone treatment 
(n= 899) 
 
 
 
 
 
 Transgender people not on CHT 
N(%) 
Transgender people on CHT 
N(%) 
 All 
(n=638) 
Transgender 
males 
(n=247) 
Transgender 
females 
(n=391) 
All  
(n=261) 
Transgender 
males 
(n=81) 
Transgender 
females 
(n=180) 
No depressive disorder (Score 0-7) 
 
334 (52.4) 125 (50.6)  209 (53.5) 169 (64.8)  52 (64.2) 117 (65.0) 
Possible or probable depressive disorder (Score ≥ 
8)  
304 (47.6) 122 (49.4) 182 (46.5) 92 (35.2) 29 (35.8) 63 (35.0) 
